OA12726A - Pharmaceutical composition based on micronized progesterone, preparaion method and uses thereof. - Google Patents

Pharmaceutical composition based on micronized progesterone, preparaion method and uses thereof. Download PDF

Info

Publication number: OA12726A
Authority: OA; OAPI
Prior art keywords: oil; progesterone; pharmaceutical composition; estradiol; composition according
Prior art date: 2001-11-13

Application number

OA1200400137A

Other languages

English (en)

French (fr)

Inventor

Antoine Besins

Jerome Besse

Original Assignee

Besins Int Belgique

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-13

Filing date

2002-11-13

Publication date

2006-06-27

2002-11-13 Application filed by Besins Int Belgique filed Critical Besins Int Belgique

2006-06-27 Publication of OA12726A publication Critical patent/OA12726A/fr

Links

RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims abstract description 92
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 28
229960001207 micronized progesterone Drugs 0.000 title claims abstract description 17
238000000034 method Methods 0.000 title claims abstract description 10
239000003921 oil Substances 0.000 claims abstract description 55
235000019198 oils Nutrition 0.000 claims abstract description 55
235000019486 Sunflower oil Nutrition 0.000 claims abstract description 24
239000002600 sunflower oil Substances 0.000 claims abstract description 23
235000008390 olive oil Nutrition 0.000 claims abstract description 13
235000019489 Almond oil Nutrition 0.000 claims abstract description 12
239000008168 almond oil Substances 0.000 claims abstract description 12
239000004006 olive oil Substances 0.000 claims abstract description 11
238000002360 preparation method Methods 0.000 claims abstract description 11
240000002791 Brassica napus Species 0.000 claims abstract description 7
235000003434 Sesamum indicum Nutrition 0.000 claims abstract description 4
230000004962 physiological condition Effects 0.000 claims abstract description 4
244000000231 Sesamum indicum Species 0.000 claims abstract 3
235000006008 Brassica napus var napus Nutrition 0.000 claims abstract 2
229960003387 progesterone Drugs 0.000 claims description 32
239000000186 progesterone Substances 0.000 claims description 32
239000000203 mixture Substances 0.000 claims description 21
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 17
239000008347 soybean phospholipid Substances 0.000 claims description 17
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 16
229960005309 estradiol Drugs 0.000 claims description 11
235000019484 Rapeseed oil Nutrition 0.000 claims description 10
235000011803 sesame oil Nutrition 0.000 claims description 10
239000000725 suspension Substances 0.000 claims description 10
239000008159 sesame oil Substances 0.000 claims description 9
239000000262 estrogen Substances 0.000 claims description 8
239000007901 soft capsule Substances 0.000 claims description 8
238000003756 stirring Methods 0.000 claims description 7
229940011871 estrogen Drugs 0.000 claims description 6
240000007817 Olea europaea Species 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 4
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 4
229960003399 estrone Drugs 0.000 claims description 4
230000028327 secretion Effects 0.000 claims description 4
244000144725 Amygdalus communis Species 0.000 claims description 3
235000011437 Amygdalus communis Nutrition 0.000 claims description 3
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 3
235000020224 almond Nutrition 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
229930182833 estradiol Natural products 0.000 claims 3
244000020551 Helianthus annuus Species 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
229940070710 valerate Drugs 0.000 claims 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract description 2
239000000787 lecithin Substances 0.000 abstract description 2
235000010445 lecithin Nutrition 0.000 abstract description 2
229940067606 lecithin Drugs 0.000 abstract description 2
244000068988 Glycine max Species 0.000 abstract 1
235000010469 Glycine max Nutrition 0.000 abstract 1
230000006259 progesterone secretion Effects 0.000 abstract 1
239000002775 capsule Substances 0.000 description 23
235000019483 Peanut oil Nutrition 0.000 description 12
239000002245 particle Substances 0.000 description 12
239000000312 peanut oil Substances 0.000 description 12
238000009472 formulation Methods 0.000 description 9
239000000243 solution Substances 0.000 description 7
244000105624 Arachis hypogaea Species 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
238000001033 granulometry Methods 0.000 description 5
230000000938 luteal effect Effects 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
235000010777 Arachis hypogaea Nutrition 0.000 description 4
206010020751 Hypersensitivity Diseases 0.000 description 4
235000020232 peanut Nutrition 0.000 description 4
239000012047 saturated solution Substances 0.000 description 4
235000017060 Arachis glabrata Nutrition 0.000 description 3
235000018262 Arachis monticola Nutrition 0.000 description 3
235000004977 Brassica sinapistrum Nutrition 0.000 description 3
241000208818 Helianthus Species 0.000 description 3
235000003222 Helianthus annuus Nutrition 0.000 description 3
206010000210 abortion Diseases 0.000 description 3
231100000176 abortion Toxicity 0.000 description 3
230000002009 allergenic effect Effects 0.000 description 3
208000026935 allergic disease Diseases 0.000 description 3
230000007815 allergy Effects 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
239000012738 dissolution medium Substances 0.000 description 3
238000009826 distribution Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000002265 prevention Effects 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
206010016946 Food allergy Diseases 0.000 description 2
208000037093 Menstruation Disturbances Diseases 0.000 description 2
208000008267 Peanut Hypersensitivity Diseases 0.000 description 2
206010036618 Premenstrual syndrome Diseases 0.000 description 2
241000207961 Sesamum Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
230000002745 absorbent Effects 0.000 description 2
239000002250 absorbent Substances 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
208000030270 breast disease Diseases 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000002285 corn oil Substances 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
229960004766 estradiol valerate Drugs 0.000 description 2
235000013350 formula milk Nutrition 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
230000029849 luteinization Effects 0.000 description 2
238000003760 magnetic stirring Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
231100000544 menstrual irregularity Toxicity 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
201000010853 peanut allergy Diseases 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000003549 soybean oil Substances 0.000 description 2
235000012424 soybean oil Nutrition 0.000 description 2
238000003860 storage Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
201000005670 Anovulation Diseases 0.000 description 1
206010002659 Anovulatory cycle Diseases 0.000 description 1
235000003276 Apios tuberosa Nutrition 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
206010006298 Breast pain Diseases 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101000807541 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 24 Proteins 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
208000006662 Mastodynia Diseases 0.000 description 1
208000017657 Menopausal disease Diseases 0.000 description 1
206010027339 Menstruation irregular Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000006399 Premature Obstetric Labor Diseases 0.000 description 1
206010036600 Premature labour Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
102100037176 Ubiquitin carboxyl-terminal hydrolase 24 Human genes 0.000 description 1
206010000496 acne Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
238000013019 agitation Methods 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
231100000552 anovulation Toxicity 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
210000004246 corpus luteum Anatomy 0.000 description 1
239000010779 crude oil Substances 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
230000006870 function Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
230000010224 hepatic metabolism Effects 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000005470 impregnation Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000036512 infertility Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
230000009245 menopause Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000003075 phytoestrogen Substances 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
208000026440 premature labor Diseases 0.000 description 1
230000001072 progestational effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000001107 psychogenic effect Effects 0.000 description 1
239000002994 raw material Substances 0.000 description 1
238000007670 refining Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229940083466 soybean lecithin Drugs 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Natural Medicines & Medicinal Plants (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Microbiology (AREA)
Alternative & Traditional Medicine (AREA)
Biotechnology (AREA)
Botany (AREA)
Medical Informatics (AREA)
Mycology (AREA)
Reproductive Health (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

OA1200400137A 2001-11-13 2002-11-13 Pharmaceutical composition based on micronized progesterone, preparaion method and uses thereof. OA12726A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0114653A FR2832065B1 (fr)	2001-11-13	2001-11-13	Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations

Publications (1)

Publication Number	Publication Date
OA12726A true OA12726A (en)	2006-06-27

Family

ID=8869332

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200400137A OA12726A (en)	2001-11-13	2002-11-13	Pharmaceutical composition based on micronized progesterone, preparaion method and uses thereof.

Country Status (24)

Country	Link
US (5)	US20030092691A1 (de)
EP (1)	EP1443940B1 (de)
KR (1)	KR100911790B1 (de)
CN (1)	CN1263453C (de)
AT (1)	ATE339958T1 (de)
AU (1)	AU2002352334B2 (de)
BR (1)	BRPI0214043B8 (de)
CY (1)	CY1106293T1 (de)
DE (1)	DE60214876T2 (de)
DK (1)	DK1443940T3 (de)
EA (1)	EA006550B1 (de)
ES (1)	ES2272793T3 (de)
FR (1)	FR2832065B1 (de)
HU (1)	HU229341B1 (de)
IL (2)	IL161668A0 (de)
MA (1)	MA27081A1 (de)
NO (1)	NO335044B1 (de)
NZ (1)	NZ532659A (de)
OA (1)	OA12726A (de)
PL (1)	PL206096B1 (de)
PT (1)	PT1443940E (de)
UA (1)	UA77451C2 (de)
WO (1)	WO2003041720A1 (de)
ZA (1)	ZA200403288B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2832065B1 (fr) *	2001-11-13	2004-11-05	Besins Int Belgique	Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
ES2592504T3 (es) *	2003-07-17	2016-11-30	Banner Life Sciences, LLC	Preparaciones de liberación controlada
US8663681B2 (en) *	2005-05-26	2014-03-04	Teva Women's Health, Inc.	Oral dosage forms comprising progesterone and methods of making and using the same
US8828981B2 (en)	2007-02-06	2014-09-09	George Creasy	Progesterone for the treatment or prevention of spontaneous preterm birth
EP2055306A1 (de) *	2007-11-05	2009-05-06	Bayer Schering Pharma AG	Verwendung eines Gestagens in Kombination mit einem Estrogen und einem oder mehreren pharmazeutisch annehmbaren hilfsstoffen/Trägern zur laktosefreien oralen Kontrazeption
FR2947178B1 (fr)	2009-06-29	2012-07-06	Effik	Composition pharmaceutique a base de progesterone micronisee et ses utilisations
CN102091054B (zh) *	2009-12-14	2014-04-16	浙江爱生药业有限公司	黄体酮制剂组合物及其制备方法
US9375437B2 (en)	2010-06-18	2016-06-28	Lipocine Inc.	Progesterone containing oral dosage forms and kits
US8951996B2 (en)	2011-07-28	2015-02-10	Lipocine Inc.	17-hydroxyprogesterone ester-containing oral compositions and related methods
MX354942B (es) *	2011-09-15	2018-03-27	Friulchem Spa	Composiciones para la administración oral a animales, procedimientos de obtención de las mismas y sus usos.
MX356017B (es)	2011-09-29	2018-05-08	Plx Opco Inc	Portadores dependientes de ph para la liberacion dirigida de productos farmaceuticos a lo largo del tracto gastrointestinal, composiciones de los mismos, y fabricacion y uso de las mismas.
EP3936133A1 (de)	2011-11-23	2022-01-12	TherapeuticsMD, Inc.	Natürliche kombinationshormonersatzformulierungen und therapien
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
EP3145489A1 (de)	2014-05-22	2017-03-29	TherapeuticsMD, Inc.	Natürliche kombinierte hormonersatzformulierungen und therapien
MX2016013693A (es)	2014-07-29	2017-10-31	Therapeuticsmd Inc	Crema transdermica.
CN107847506A (zh)	2015-06-22	2018-03-27	来普卡公司	含17‑羟基孕酮酯的口服组合物和相关方法
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
EP3435977A4 (de)	2016-04-01	2019-10-16	Therapeuticsmd, Inc.	Pharmazeutische steroidhormonzusammensetzung
EP3395332A1 (de)	2017-04-28	2018-10-31	Chemo Research, S.L.	Hormon-softgelkapseln und verfahren zur herstellung davon
US10285998B1 (en)	2018-04-04	2019-05-14	The Menopause Method, Inc.	Composition and method to aid in hormone replacement therapy
US11576920B2 (en)	2019-03-18	2023-02-14	The Menopause Method, Inc.	Composition and method to aid in hormone replacement therapy
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
KR20220158031A (ko)	2020-03-26	2022-11-29	피엘엑스 옵코 인코포레이티드	pH 의존성 재구성이 가능한 제약 담체 및 그의 제조 및 사용 방법
EP4389117A1 (de)	2022-12-19	2024-06-26	Besins Healthcare Distribution FZ-LLC	Progesteronformulierung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2408345A1 (fr) *	1976-11-30	1979-06-08	Besins Jean Louis	Nouvelle composition a action anti-conceptionnelle
JPS60258110A (ja) *	1984-06-05	1985-12-20	Daigo Eiyou Kagaku Kk	静脈注射可能なプロゲステロン乳化注射液
US5140021A (en) *	1986-04-16	1992-08-18	Genesis Systems Corporation	Method and dosage form for treatment of premenstrual syndrome
IE61236B1 (en) *	1986-07-15	1994-10-19	American Home Prod	Combination dosage form for pre-menopausal women
IT1256386B (it) *	1992-11-13	1995-12-04	Luigi Boltri	Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo
DE69402297T2 (de) *	1993-12-22	1997-07-10	Oreal	Kosmetisches oder dermatologisches Pulver, Verfahren zu seiner Herstellung und Verwendungen
FR2747042B1 (fr) *	1996-04-05	1998-06-05	Besins Iscovesco Lab	Medicament a base de progesterone et d'oestradiol
GB9608719D0 (en) *	1996-04-26	1996-07-03	Scherer Ltd R P	Pharmaceutical compositions
US6861415B2 (en) *	1996-05-01	2005-03-01	The United States Of America As Represented By The Department Of Health And Human Services	21-substituted progesterone derivatives as new antiprogestational agents
FR2777784B1 (fr) *	1998-04-27	2004-03-19	Arepa	Composition pharmaceutique a base d'estrogene et de progesterone
FR2832065B1 (fr)	2001-11-13	2004-11-05	Besins Int Belgique	Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations

2001
- 2001-11-13 FR FR0114653A patent/FR2832065B1/fr not_active Expired - Fee Related
2002
- 2002-03-14 US US10/097,526 patent/US20030092691A1/en not_active Abandoned
- 2002-11-13 AT AT02788051T patent/ATE339958T1/de active
- 2002-11-13 ES ES02788051T patent/ES2272793T3/es not_active Expired - Lifetime
- 2002-11-13 BR BRPI0214043A patent/BRPI0214043B8/pt not_active IP Right Cessation
- 2002-11-13 EP EP02788051A patent/EP1443940B1/de not_active Expired - Lifetime
- 2002-11-13 KR KR1020047007199A patent/KR100911790B1/ko not_active Expired - Fee Related
- 2002-11-13 OA OA1200400137A patent/OA12726A/fr unknown
- 2002-11-13 IL IL16166802A patent/IL161668A0/xx unknown
- 2002-11-13 CN CNB028224868A patent/CN1263453C/zh not_active Expired - Lifetime
- 2002-11-13 HU HU0401935A patent/HU229341B1/hu unknown
- 2002-11-13 PL PL369131A patent/PL206096B1/pl unknown
- 2002-11-13 WO PCT/FR2002/003879 patent/WO2003041720A1/fr active IP Right Grant
- 2002-11-13 UA UA20040503542A patent/UA77451C2/uk unknown
- 2002-11-13 US US10/495,242 patent/US7431941B2/en not_active Expired - Lifetime
- 2002-11-13 NZ NZ532659A patent/NZ532659A/en not_active IP Right Cessation
- 2002-11-13 AU AU2002352334A patent/AU2002352334B2/en not_active Expired
- 2002-11-13 EA EA200400668A patent/EA006550B1/ru unknown
- 2002-11-13 DK DK02788051T patent/DK1443940T3/da active
- 2002-11-13 DE DE60214876T patent/DE60214876T2/de not_active Expired - Lifetime
- 2002-11-13 PT PT02788051T patent/PT1443940E/pt unknown
2004
- 2004-04-29 IL IL161668A patent/IL161668A/en active IP Right Grant
- 2004-04-30 ZA ZA2004/03288A patent/ZA200403288B/en unknown
- 2004-05-04 MA MA27665A patent/MA27081A1/fr unknown
- 2004-05-14 NO NO20042002A patent/NO335044B1/no not_active IP Right Cessation
2006
- 2006-12-18 CY CY20061101808T patent/CY1106293T1/el unknown
2008
- 2008-02-27 US US12/071,822 patent/US7829115B2/en not_active Expired - Lifetime
2010
- 2010-11-01 US US12/916,795 patent/US20110135719A1/en not_active Abandoned
2012
- 2012-07-05 US US13/542,164 patent/US8435561B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1443940A1 (de)	2004-08-11
PL206096B1 (pl)	2010-06-30
BR0214043A (pt)	2004-10-13
FR2832065A1 (fr)	2003-05-16
AU2002352334B2 (en)	2008-10-23
BRPI0214043B1 (pt)	2019-12-31
DK1443940T3 (da)	2007-01-29
HUP0401935A2 (hu)	2005-01-28
NO335044B1 (no)	2014-09-01
HUP0401935A3 (en)	2011-02-28
DE60214876D1 (de)	2006-11-02
US7829115B2 (en)	2010-11-09
CN1585644A (zh)	2005-02-23
PT1443940E (pt)	2007-01-31
US20050004076A1 (en)	2005-01-06
US20120276194A1 (en)	2012-11-01
ATE339958T1 (de)	2006-10-15
EP1443940B1 (de)	2006-09-20
ES2272793T3 (es)	2007-05-01
NO20042002L (no)	2004-05-14
CY1106293T1 (el)	2011-10-12
MA27081A1 (fr)	2004-12-20
US8435561B2 (en)	2013-05-07
BRPI0214043B8 (pt)	2021-05-25
DE60214876T2 (de)	2007-04-05
IL161668A0 (en)	2004-09-27
KR20050058231A (ko)	2005-06-16
IL161668A (en)	2009-09-01
EA200400668A1 (ru)	2004-10-28
EA006550B1 (ru)	2006-02-24
FR2832065B1 (fr)	2004-11-05
US7431941B2 (en)	2008-10-07
PL369131A1 (en)	2005-04-18
NZ532659A (en)	2006-04-28
ZA200403288B (en)	2005-07-27
WO2003041720A1 (fr)	2003-05-22
US20090123534A1 (en)	2009-05-14
CN1263453C (zh)	2006-07-12
KR100911790B1 (ko)	2009-08-12
US20110135719A1 (en)	2011-06-09
UA77451C2 (en)	2006-12-15
HU229341B1 (en)	2013-11-28
US20030092691A1 (en)	2003-05-15
HK1064606A1 (en)	2005-02-04

Publication	Publication Date	Title
EP1443940B1 (de)	2006-09-20	Arzneizusammensetzung bestehend aus mikronisiertem progesteron, verfahren zu ihrer herstellung und ihre verwendungen
EP2269592B1 (de)	2013-08-07	Pharmazeutische Zusammensetzung von mikronisiertem Progesteron und Verwendung derselben
CA2518200A1 (fr)	2004-09-23	Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
DK2523666T3 (en)	2016-04-04	A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
JP2005515996A (ja)	2005-06-02	活性型ビタミンｄ化合物を含む薬学的組成物
EP0275224A2 (de)	1988-07-20	Phospholipidische Komplexe aus Vitis Vinifera-Extrakten, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische und kosmetische Zusammensetzungen
FR2988611A1 (fr)	2013-10-04	Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations
EP1363641A1 (de)	2003-11-26	Mit einem tensid co-mikronisiertes progestin, pharmazeutische zusammensetzung dieses enthaltend, verfahren zu deren herstellung sowie verwendung
JPH11512115A (ja)	1999-10-19	経口投与用製剤組成物
WO2014001729A2 (fr)	2014-01-03	Compositions pour application topique comprenant un extrait naturel de plante
EP1691808A1 (de)	2006-08-23	Pharmazeutische zusammensetzung für die orale verabreichung eines pyrazol-3-carbonsäurederivats
FR2888509A1 (fr)	2007-01-19	Extraits de ginkgo biloba
EP3593789A1 (de)	2020-01-15	Zusammensetzung, die ein derivat von 7beta-hydroxycholesterol und einen lipidträger enthält, und ihre verwendung zur behandlung von neoplasien
LU87777A1 (fr)	1990-12-11	Nouvelle forme galenique orale ameliorant la biodisponibilite
IT202200021093A1 (it)	2024-04-13	Metodo per ottenere nanoparticelle lipidiche solide a partire da saponi naturali
HK1064606B (en)	2006-11-17	Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof